立体定向放射联合替吉奥治疗晚期胰腺癌临床观察

来源 :第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 | 被引量 : 0次 | 上传用户:pheihe
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  目的:探讨立体定向放射治疗联合口服替吉奥(s-1)治疗晚期胰腺癌的疗效。方法:将83例晚期胰腺癌患者随机分立体定向放射治疗组和立体定向放射+替吉奥治疗组,分别观察不良反应和疗效。
其他文献
Objective: The aim of this study was to investigate the clinicopathological and prognostic relevance of metastasis associated with colon cancer 1 (MACC1), C-Met and terminus tensin-like molecule (CTEN
Objective: Despite the improved patient care and the declined mortality rate, gastric cancer is still a leading cause of cancer deaths worldwide, particularly in Asia.
Objective: Preoperative concurrent chemoradiotherapy (chemoRT) has been established as the standard of care for patients with cT3-4 rectal cancer.As an alternative strategy, we launched a randomized p
Objective: The study aims to investigate the prevalence of, and factors influencing, preoperative anxiety and depression in gastric cancer patients in China.The results of this study will provide scie
Objective: PFTK1, also known as PFTAIRE1, CDK14, is a novel member of Cdc2-related serine/threonine protein kinases.Recent studies show that PFTK1 is highly expressed in several malignant tumors such
Objective: To identity specific long non-coding RNAs (lncRNAs) involved in distant metastasis of gastric cancer (GC).Method: Differentially expressed mRNAs and lncRNAs between stage Ⅳ and non-stage Ⅳ
Objective: To observe the clinical efficacy and adverse reactions of oxaliplatin combined with S-1 or gemcitabine as first-line chemotherapy for patients with biliary tract cancer.
Objective: The overall survival is poor for patients with thoracic esophageal cancer.The major reason is the high rate of lymph node metastases.However, recent studies found that the number of negativ
Objective: Genetic and epigenetic pathways are not independent in colorectal cancer (CRC) carcinogenesis.We aimed to determine the influence of various molecular features on Chinese patients colon can
Objective: This single-center, open-label, randomized, controlled trial aimed to evaluate the efficacy and safety of ginsenoside Rg3, a low toxicity vascular-endothelial growth factor (VEGF) inhibitor